AMAnn McCann

Ann McCann

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article


Ann McCann has a total of 43 co-authors. Here are the top co-authors by number of shared publications:


Latest Publications

  • Assessment of the extremity exposure during preparation and administration of 177 Lu – results of a multi-center study

    by Robert Kollaard, Łukasz Albiniak, Nicolas Cherbuin, Jérémie Dabin, Hanan Datz, Mahila Ferrari, Mikko Hakulinen, Sigalit Haruz-Waschitz, Tereza Kráčmerová, Ann McCann, et al.

    Despite the increased use of 177 Lu in nuclear medicine (NM) over the last 10 years, the knowledge of the actual exposure of the extremities due to manipulation of this pharmaceutical is limited. The purpose of this study is to assess the extremity dose during the preparation and administration of 177 Lu-labelled radiopharmaceuticals in a wide range of NM practices. Workers in 10 NM centres throughout Europe wore a ring dosimeter on the base of the index finger of the non-dominant hand during preparation and/or administration of 177 Lu-labelled radiopharmaceuticals. Information on manipulated activity, tasks performed and protection measures was collected to allow sub-analyses. The median ring dose per monitoring interval was 0.16 mSv, with a maximum of 2.27 mSv in one month. The median normalised dose amounted 3.5 µ Sv GBq −1 (range 0.5–525). The highest monthly doses were found for workers involved in preparation of the pharmaceutical. The workers performing manual administrations (6.5 µ Sv GBq −1 ) showed higher normalised ring doses than those using the gravity method (3.5 µ Sv GBq −1 ) or a syringe pump (1.0 µ Sv GBq −1 ). Explanations for the wide range of normalised ring doses may be found in the different techniques applied in this study and the differences in minimum reportable doses of the dosimeters. When the data is extrapolated using a fingertip to ring dose ratio of 5, an annual fingertip dose of 1–136 mSv is found, with a median fingertip dose of 10 mSv per year. Extremity exposure during 177 Lu handling remained well below dose limits. The highest normalised doses occurred during preparation and manual administration. Overall, this investigation shows doses remain low when appropriate radiation protection measures (e.g. shielding and minimising time at short distance) are being applied.

  • Optimising 68Ga-SSTR PET radiomic feature extraction towards improved feature stability and predictive classification models for small neuroendocrine tumours

    by Ann McCann, Mathilde Colombie, Luis León Vintró, Seán Cournane, Hussein Almeamar, Lucian Harris, Anita Dowling, Julie Lucey

  • Open Access

    Monte Carlo study of the eye lens exposure of medical staff administering Sc-47 and Cu-67 labelled radiopharmaceuticals

    by P. Ferrari, F. Becker, J. Dabin, J. Eakins, Z. Jovanović, D. Krstić, E. Michaś-Majewska, K. Tymińska, A. Benali, R. Bouwman, et al.


  • THE EURADOS EXPERIENCE ON EXTREMITY EXPOSURE OF WORKERS IN NUCLEAR MEDICINE

    by A. Zorz, N. Cherbuin, P. Covens, L. Cunha, A. Mccann, J. Dabin, R. Kollaard


  • Open Access

    Finger doses due to 68Ga-labelled pharmaceuticals in PET departments—results of a multi-centre pilot study

    by Ann McCann, Nicolas Cherbuin, Peter Covens, Jérémie Dabin, Sigalit Haruz-Waschitz, Lara Gallo, Hanan Datz, Roel Wierts, Malgorzata Wrzesien, Alessandra Zorz, et al.

    Introduction: Although the use of 68Ga has increased substantially in nuclear medicine over the last decade, there is limited information available on occupational exposure due to 68Ga. The purpose of this study is to determine the occupational extremity exposure during the preparation, dispensing and administration of 68Ga-labelled radiopharmaceuticals. Method: Workers in eight centres wore a ring dosimeter for all tasks involving 68Ga-labelled radiopharmaceuticals for a minimum of one month. Additionally, the fingertip dose was monitored in two centres and the hand with the highest ring dose during 68Ga procedures was also identified in one centre. Results: The median normalised ring dose for 68Ga procedures was found to be 0.25 mSv GBq−1 (range 0.01–3.34). The normalised 68Ga ring doses recorded in this study are similar to that found in the literature for 18F. This study is consistent with previous findings that the highest extremity dose is found on the non-dominant hand. A limited sub study in two of the centres showed a median fingertip to base of the finger dose ratio of 4.3. Based on this median ratio, the extrapolated annual 68Ga fingertip dose for 94% of the workers monitored in this study would be below Category B dose limit (150 mSv) and no worker would exceed Category A dose limit (500 mSv). Conclusion: When appropriate shielding and radiation protection practices are employed, the extremity dose due to 68Ga is comparable to that of 18F and is expected to be well below the regulatory limits for the majority of workers.


  • Open Access

    Assessment of occupational exposure from shielded and unshielded syringes for clinically relevant positron emission tomography (PET) isotopes—a Monte Carlo approach using EGSnrc

    by Ann McCann, Luis León Vintró, Seán Cournane, Julie Lucey

    18F has been the most widely used radionuclide in positron emission tomography (PET) facilities over the last few decades. However, increased interest in novel PET tracers, theranostics and immuno-PET has led to significant growth in clinically used positron-emitting radionuclides. The decay schemes of each of these radioisotopes are markedly different from 18F, with different endpoint energies for the emitted positrons and, in some cases, additional high energy gamma radiation. This has implications for the occupational exposure of personnel involved in the manipulation and dispensing of PET radiopharmaceuticals. The EGSnrc Monte Carlo simulation software was used to estimate the doses to extremities in contact with unshielded and shielded syringes containing 64Cu, 18F, 11C, 13N, 15O, 68Ga and 89Zr, respectively. Dose rates at various distances from the syringe were also modelled, with dose rates reported in terms of eye (Hp(3)), skin equivalent (Hp(0.07)) and deep (Hp(10)) doses. The composition and geometry of the simulated syringe shields were based on a selection of commercially available PET shields. Experimental dose rate measurements were performed for validation purposes where possible. Contact skin dose rates for all isotopes, except for 64Cu, were found to be higher than 18F for the unshielded syringe. The addition of a shield resulted in approximately equal contact skin dose rates for nearly all isotopes, for each shield type, with the exception of 89Zr which was notably higher. Dose rate constants (µGy/MBq.hr) for a range of PET isotopes and shields are presented and their significance discussed.